PRESS RELEASES More events are coming soon. Keyword Search Year: 20202019201820172016201520142013 05/14/20 Summary ToggleTRACON Pharmaceuticals Announces Presentation of Positive Clinical Data for Envafolimab in MSI-H/dMMR Cancer at ASCO 2020 Virtual Scientific Program by its Corporate Partners 3D Medicines and Alphamab Printer Friendly PDF Version 05/13/20 Summary ToggleTRACON Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update Printer Friendly PDF Version 05/11/20 Summary ToggleTRACON Pharmaceuticals Announces Successful Type B Meeting with FDA for Pivotal Study of Envafolimab in Sarcoma Printer Friendly PDF Version 05/06/20 Summary ToggleTRACON to Report First Quarter 2020 Financial Results and Company Highlights on May 13, 2020 Printer Friendly PDF Version 04/24/20 Summary ToggleTRACON Pharmaceuticals Retains Global Rights to TRC253 Following Completion of a Phase 1/2 Trial Printer Friendly PDF Version 04/14/20 Summary ToggleTRACON Pharmaceuticals Announces Appointment of Biotechnology Industry Veteran Shahe Garabedian as Senior Vice President of Quality Assurance and Granting of Inducement Award Printer Friendly PDF Version 04/06/20 Summary ToggleTRACON Announces May 8 Date for Type B Teleconference Meeting with FDA to Discuss Trial Design for ENVASARC: A Potential Pivotal Study of Envafolimab in Sarcoma Printer Friendly PDF Version 03/19/20 Summary ToggleTRACON Pharmaceuticals Announces Appointment of Saundra Pelletier to Board of Directors Printer Friendly PDF Version 03/16/20 Summary ToggleTRACON Announces Submission of Request for Type B Meeting with FDA to Discuss Trial Design for ENVASARC: A Potential Pivotal Study of Envafolimab in Sarcoma Printer Friendly PDF Version 03/09/20 Summary ToggleSanten and TRACON Discontinue Development of DE-122 for Wet Age-Related Macular Degeneration Printer Friendly PDF Version Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last
